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Abstract
BACKGROUND—St. Louis encephalitis virus is a mosquito-borne flavivirus that infrequently 
causes epidemic central nervous system infections. In the United States, blood donors are not 
screened for St. Louis encephalitis virus infection, and transmission through blood transfusion has 
not been reported. During September 2015, St. Louis encephalitis virus infection was confirmed in 
an Arizona kidney transplant recipient. An investigation was initiated to determine the infection 
source.
STUDY DESIGN AND METHODS—The patient was interviewed, and medical records were 
reviewed. To determine the likelihood of mosquito-borne infection, mosquito surveillance data 
collected at patient and blood donor residences in timeframes consistent with their possible 
exposure periods were reviewed. To investigate other routes of exposure, organ and blood donor 
and recipient specimens were obtained and tested for evidence of St. Louis encephalitis virus 
infection.
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RESULTS—The patient presented with symptoms of central nervous system infection. Recent St. 
Louis encephalitis virus infection was serologically confirmed. The organ donor and three other 
organ recipients showed no laboratory or clinical evidence of St. Louis encephalitis virus 
infection. Among four donors of blood products received by the patient via transfusion, one donor 
had a serologically confirmed, recent St. Louis encephalitis virus infection. Exposure to an 
infected mosquito was unlikely based on the patient’s minimal outdoor exposure. In addition, no 
St. Louis encephalitis virus-infected mosquito pools were identified around the patient’s residence.
CONCLUSION—This investigation provides evidence of the first reported possible case of St. 
Louis encephalitis virus transmission through blood product transfusion. Health care providers and 
public health professionals should maintain heightened awareness for St. Louis encephalitis virus 
transmission through blood transfusion in settings where outbreaks are identified.
St. Louis encephalitis virus (SLEV) is a mosquito-borne flavivirus closely related to West 
Nile virus (WNV). These viruses share the same mosquito vectors, and their associated 
disease presentations are clinically indistinguishable.1 Like WNV, SLEV is primarily 
maintained and amplified through cycles between Culex species mosquitoes and avian hosts, 
and their geographic and temporal distribution dictates the occurrence of human 
infections.2–5 Most SLEV infections are asymptomatic, but they also can result in a 
nonspecific febrile illness.3 Less than 1% of human SLEV infections lead to severe 
neuroinvasive disease, which can present as encephalitis, meningitis, or acute flaccid 
paralysis; individuals ages 55 years and older are at higher risk for developing SLEV 
neuroinvasive disease.3,6–8 SLEV infection can be diagnosed by molecular or serologic 
testing. The viremic period is transient; thus, ribonucleic acid (RNA) is seldom detectable in 
acute infections that are evaluated after the onset of symptoms, and serology is the mainstay 
of diagnosis. However, because antibodies against SLEV and WNV readily cross-react on 
immunoglobulin (Ig)M diagnostic tests, confirmatory neutralizing antibody testing is 
required to identify the specific infecting flavivirus.9
SLEV was first identified in St. Louis, Missouri, in 1933, and more than 50 outbreaks have 
been reported in the United States since then.10,11 Reports of SLEV neuroinvasive disease 
declined considerably after WNV was first detected in 1999; however, isolated cases and 
limited outbreaks of SLEV disease still occur sporadically in the United States.1,2,12 SLEV 
is a nationally notifiable infectious disease. In 2015, Arizona state and local health 
authorities identified an outbreak of SLEV during which infection was confirmed in 23 
symptomatic persons. Arizona was the only US state to report human SLEV disease cases to 
the Centers for Disease Control and Prevention (CDC) that year. In addition, acute WNV 
disease cases were also confirmed, making this the first documented concurrent outbreak of 
WNV and SLEV in the United States.13 The majority of SLEV disease cases were reported 
in Maricopa County, which is the largest urban area in Arizona. Although the blood supply 
in the United States has attained an unprecedented level of safety, it remains vulnerable to 
emerging infectious agents.14 WNV transmission by blood transfusion in the United States 
has been well documented and is rarely reported since the implementation of routine 
screening of blood donors for WNV infection by nucleic-acid testing (NAT).15–17 Blood 
donor screening for Zika virus, another related flavivirus, was implemented in 2016.18 
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SLEV transmission by blood transfusion has not previously been reported.17 There are no 
US Food and Drug Administration (FDA)-licensed blood donor screening tests for SLEV.
During September 2015, the United Network for Organ Sharing alerted CDC of suspected 
neuroinvasive SLEV disease in a kidney transplant recipient in Maricopa County on the 
basis of the detection of SLEV IgM antibodies in his serum. This patient is referred to 
hereinafter as the SLEV recipient. The organ recipient care teams, Arizona Department of 
Health Services, and Maricopa County Department of Public Health were notified. The 
objectives of the ensuing public health investigation were to confirm the diagnosis of SLEV 
infection in the recipient and to determine the source of his infection.
MATERIALS AND METHODS
SLEV recipient
The SLEV recipient was interviewed regarding exposure history and clinical course, and his 
medical records were reviewed. Residual serum specimens collected before organ 
transplantation and after neuroinvasive disease symptom onset, as well as residual 
cerebrospinal fluid (CSF) collected after symptom onset were obtained for SLEV and WNV 
testing. There were no remaining specimens collected between day of transplant and 
symptom onset.
Case definition
An SLEV disease case was classified according to clinical and laboratory criteria stipulated 
in the national case definition for reporting of arboviral diseases.19 In addition, any persons 
who had laboratory evidence of recent SLEV infection within 4 weeks after receipt of an 
organ or blood component from a donor with evidence of recent SLEV infection was 
considered to have a possible transplant-transmitted or transfusion-transmitted infection, 
respectively. SLEV infection was considered confirmed if there was molecular detection of 
SLEV RNA or if serologic testing was positive for SLEV IgM with the detection of 
neutralizing antibodies to SLEV at a titer 4-fold higher than WNV.
Organ donor and other organ recipients
The organ donor’s medical records were reviewed, and residual serum, plasma, and lymph 
node DNA lysate collected before organ recovery were obtained for flavivirus testing. Other 
recipients of organs from the same donor were contacted to obtain symptom history and 
serum specimens for SLEV and WNV testing.
Blood donors and other blood product recipients
Medical records were reviewed to determine whether the SLEV recipient had received any 
blood products before symptom onset. The blood collection center initiated a lookback 
investigation to determine whether there were any remaining in-date co-components that 
needed to be quarantined and tested for SLEV RNA. The donors of all identified blood 
products were contacted to obtain symptom history, residence address at the time of 
donation, and serum specimens for SLEV testing.
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Laboratory testing
Serum and CSF samples were tested for the presence of anti-SLEV and anti-WNV IgM and 
IgG using an enzyme-linked immunosorbent assay at the state public health laboratory, and 
for anti-WNV IgM using a microsphere-based immunosorbent assay at the CDC.20 For 
serum specimens with IgM test results reported as positive or nonspecific, confirmatory 
plaque reduction neutralization testing (PRNT) using a 90% reduction in the number of 
plaques (PRNT90) for SLEV and WNV was performed at the CDC.21 Tissue specimens 
were tested by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry at 
the CDC.
Mosquito surveillance
The Maricopa County Environmental Services (MCES) Vector Control Division routinely 
conducted mosquito surveillance in 2015 for WNV and SLEV because of the circulation of 
both viruses in the region. Traps were placed throughout Maricopa County to collect Culex 
species mosquitoes. MCES recorded the number and location of mosquito traps and tested 
all mosquitoes captured using RT-PCR for both WNV and SLEV; mosquitoes from the same 
trap were tested in pools.22 To determine whether SLEV was circulating in the areas in 
which the SLEV patient might have been exposed to mosquitoes, suggesting a greater 
likelihood of vector-borne transmission, MCES reviewed data from mosquito surveillance 
conducted during the 30 days before the date of his illness onset for both the area of his 
residence and the hospital where he was admitted. Similarly, MCES reviewed the data for 
areas of residence of any implicated donors for 30 days before organ or blood donation. A 5-
mile radius around each of the sites was chosen based on the average maximum flight range 
combined for both adult C. tarsalis and C. quinquefasciatus mosquitoes from a previous 
dispersal study.23
RESULTS
SLEV recipient
The SLEV recipient was a 69-year-old man who was admitted to the hospital in late July 
2015 for a kidney transplant because of end-stage renal disease, which was attributed to 
diabetic nephropathy and hypertension (Fig. 1). He received methylprednisolone and 
induction therapy with basiliximab to prevent organ rejection; tacrolimus was added 2 days 
after transplant. The patient received transfusions of 4 units of leukocyte-reduced red blood 
cells (pRBCs) on Days 1, 2, 20, and 21 after transplant and was discharged home 34 days 
after transplant.
The day after discharge, he experienced headache, fever, fatigue, nausea, diarrhea, shortness 
of breath, and chills, which progressed to rigors. Upon initial consultation, his physicians 
attributed his symptoms to bacteremia secondary to ureteral stent removal; however, he was 
readmitted 37 days after transplant, when his symptoms progressed to lower extremity 
paralysis and respiratory distress, requiring a tracheostomy. By Day 43, the patient’s mental 
status began to deteriorate. Serum and CSF specimens were collected on Day 43 to test for 
possible flavivirus infection, and empiric antibiotics were started for possible bacterial 
infection. The patient received intravenous immunoglobulin and interferon therapy from Day 
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44 to Day 48 after transplant and 1 pRBC unit each on Days 49 and 56. On Day 51, the 
patient exhibited gradual motor function improvement, and he had cognitive improvement 
by Day 59. The patient was discharged to home on Day 105 and experienced some 
neurologic sequelae after discharge, including memory loss and weakness.
Residual serum specimens collected 16 days before and on the day of his transplant, 
respectively, were obtained for testing. The serum specimens had nonspecific results on 
WNV and SLEV IgM testing but had no detectable neutralizing antibodies to SLEV or 
WNV, ruling out prior infection. The IgM results likely reflect either prior flavivirus 
infection or reactivity to other serum factors. Testing of subsequent samples, which were 
collected on the day of symptom onset and beyond, confirmed seroconversion on PRNT as 
well as a greater than fourfold increase in SLEV neutralizing antibody titers between serum 
collected on Day 35 (PRNT = 20) and Day 43 (PRNT = 1280). Neutralizing antibody titers 
against SLEV were also more than four-fold higher than titers against WNV (Table 1). The 
SLEV recipient’s presentation and test results thus met the clinical and laboratory criteria for 
neuroinvasive SLEV infection. Upon subsequent interview, the patient reported no febrile 
illness, exposure to mosquitoes, or travel out of state before transplant. The SLEV recipient 
spent minimal time outdoors during the weeks before symptom onset, because he was 
hospitalized with limited mobility. The only noted history of flavivirus exposure was receipt 
of a yellow fever vaccination in 1965. The patient continued to recover; and, by April 2016, 
he was reportedly back to neurological baseline.
Organ donor and other organ recipients
The cadaveric donor of the left kidney transplanted into the SLEV recipient died in July 
2015 in Illinois. His heart, liver, and right kidney were also recovered and transplanted. 
According to his medical record, he had no symptoms suggestive of flavivirus infection. The 
heart and liver recipients were Illinois residents, and the right kidney recipient was an 
Arizona resident; none of these recipients had symptoms compatible with flavivirus 
infection after transplantation. Organ donor serum collected 1 day before organ recovery 
contained no detectable SLEV RNA, and IgM antibody test results were negative. There was 
no SLEV RNA or SLEV antigen detected in residual lymph node tissue by RT-PCR or 
immunohistochemistry, respectively. Serum specimens collected 6 weeks after organ 
transplant from the heart recipient and right kidney recipient had no evidence of recent 
infection. No specimens were available for testing from the liver recipient.
Blood donors and other blood product recipients
The four pRBC units that the SLEV recipient received before symptom onset were collected 
from four blood donors (Donors A, B, C, and D) whose blood products were delivered by 
transfusion on Day 1 (Donor A), Day 2 (Donor B), Day 20 (Donor C), and Day 21 (Donor 
D) after transplant. The donated blood products had been screened by WNV NAT at the 
blood collection agency and were negative. There were no remaining blood products 
available for testing. Serum was collected from these donors from 73 to 85 days after the 
date of donation for SLEV and WNV testing. Specimens from Donors A, B, and D 
contained no detectable IgM or neutralizing antibodies against SLEV or WNV. Serum from 
Donor C, collected 77 days after donation, tested positive for SLEV and negative for WNV 
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IgM by microsphere-based immunosorbent assay. The specimen from blood Donor C had 
detectable neutralizing antibodies against SLEV (PRNT = 320) but not against WNV (PRNT 
<10). This donor did not report any symptoms compatible with flavivirus infection before or 
after donating blood.
The recipient of the fresh-frozen plasma co-component from Donor C’s donation was a 77-
year-old woman who received a transfusion after she was admitted to the hospital in late 
July 2015. She had altered mental status before the blood transfusion and received multiple 
units of fresh-frozen plasma and platelets while admitted. After approximately 2 weeks of 
hospitalization, she was transferred to hospice, where she died 3 days later. Her primary 
diagnoses upon discharge to hospice were toxic metabolic encephalopathy, subdural 
hematoma, and possible hemolytic anemia/thrombotic thrombocytopenic purpura. The cause 
of death was not suspected to be a flavivirus infection. No autopsy was conducted. Although 
no specimens were available for testing, a medical records review did not indicate febrile 
illness or exacerbation of neurologic features after the transfusion.
Mosquito surveillance
Approximately 50 traps had been placed within a 5-mile radius of the SLEV recipient’s 
residence, Donor C’s residence, and the hospital where the SLEV recipient was admitted. 
Traps were observed for mosquitoes by MCES on a weekly basis. No SLEV-infected 
mosquitoes were identified from 11 mosquito pools from traps collected within a 5-mile 
radius around the index patient’s residence (Fig. 2) (only traps that trapped live mosquitoes 
are shown in the figure). No SLEV-infected mosquitoes were identified from 37 mosquito 
pools from traps collected within a 5-mile radius around the hospital location. Ten SLEV-
infected mosquitoes (nine C. quinquefasciatus and one C. tarsalis species) were identified 
from 112 mosquito pools from traps collected within a 5-mile radius around Donor C’s 
residence.
DISCUSSION
To our knowledge, this is the first reported case of possible SLEV transmission through 
blood product transfusion. The patient experienced a clinical illness compatible with SLEV 
infection 15 days after receiving blood products from an asymptomatic donor with 
serologically confirmed, recent SLEV infection. The interval between transfusion and 
symptom onset is consistent with the estimated incubation period for mosquito-transmitted 
SLEV infection (range, 5–15 days), which has been documented as prolonged (median, 13.5 
days) in immunocompromised recipients with transfusion-associated WNV infection.16 The 
timing of SLEV infection after the implicated transfusion is also supported by 
seroconversion from neutralizing antibodies being undetectable before the transfusion to 
being detectable and progressively increasing after the transfusion. This case was likely 
detected because of enhanced surveillance and testing systems in place for the concurrent 
WNV and SLEV outbreaks in the region.13 Mosquito surveillance data demonstrated the 
detection of SLEV infected mosquitoes around Donor C’s residence but not around the 
SLEV recipient’s residence or the hospital, indicating that the SLEV recipient might have 
been at lower risk of mosquito-borne exposure. However, these data were not directly 
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comparable, because many more mosquito pools were tested in the region of the blood 
donor’s residence. In addition, the SLEV recipient spent all of his potential exposure period 
indoors while hospitalized, except for 1 day spent at home. Serologic test results indicating 
recent SLEV infection in both the index patient, after the implicated transfusion, and Blood 
Donor C support SLEV transmission through Blood Donor C’s blood products.
Human SLEV infection is most commonly acquired from Culex species mosquito bites; 
however, other less common routes of transmission are possible. One case of laboratory-
acquired SLEV infection has been previously described.24 Although transmission of SLEV 
through blood transfusion has not been documented in the published literature, transmission 
of flavivirus infections through blood transfusion is known to occur.15,25–27 In Arizona, 
blood products are routinely screened for WNV by NAT.18,28 There is no FDA requirement 
or AABB standard for screening blood products for SLEV, and there are no SLEV NAT 
assays commercially available and approved for blood donor screening.
The benefit of blood product screening for blood-borne pathogens depends on several 
factors, including disease incidence and severity of outcome; screening has proven effective 
in reducing transfusion transmission of WNV, for example.29 Reported SLEV disease 
incidence nationwide is extremely low; an average of seven SLEV disease cases were 
reported annually in the United States during 2004 through 2013 compared with an average 
of 2540 WNV disease cases reported annually during that same period. This would limit the 
benefit of screening blood donors for SLEV infection.30 The low US incidence makes the 
positive predictive value of any SLEV blood product screening test much lower than that for 
WNV. The duration of donor SLEV infectious risk is assumed to be similar to that for WNV; 
and, in this case, the local blood collection agency issued a recommendation once 
confirmatory testing was completed for the asymptomatic blood donor for a 120-day donor 
deferral period based on the same period stipulated for WNV NAT-positive blood donors.31
This investigation had multiple limitations. There were no residual specimens from Blood 
Donor C’s implicated donation to confirm the presence of SLEV in any of the donated blood 
products, which would have strengthened evidence for transfusion-related transmission of 
SLEV. We also could not definitely state when Blood Donor C’s SLEV viremia occurred, 
because we only had serologic confirmation of recent infection. Specimens were also 
unavailable for the plasma recipient, because the investigation took place several weeks after 
she had died.
This investigation provides evidence to support the possibility that SLEV, like WNV, can be 
transmitted through blood products, reinforcing the importance of public health surveillance 
for SLEV disease, especially during an outbreak. Public health officials could determine 
whether there is an increased risk for SLEV transmission in an area and alert physicians to 
consider SLEV if there is neuroinvasive disease in a blood transfusion recipient. This should 
prompt a public health investigation to determine whether the infection might have been 
transfusion or transplant derived. Current public health surveillance data may under 
represent the true burden of SLEV disease because of the infrequent availability of SLEV 
laboratory testing and cross-reactivity with WNV testing. In the absence of systematic data 
on the risk of transfusion transmission of SLEV, there is currently no justification for routine 
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blood screening; however, continued vigilance for cases like that described herein should 
inform risk-based decisions on whether further mitigation measures are required. Health 
care providers and public health professionals should maintain heightened awareness for 
SLEV transmission through blood transfusion in settings in which SLEV transmission is 
identified.
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Fig. 1. 
Investigation timeline of possible St. Louis encephalitis virus transmission through blood 
transfusion relative to the timing of transplantation of the infected kidney recipient: Arizona, 
2015.
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Fig. 2. 
Mosquito surveillance* for St. Louis encephalitis virus in a 5-mile radius of case locations 
and donor location for a 30-day period before recipient symptom onset and donor blood 
donation: Maricopa County, Arizona, 2015. *Fifty traps were located within each 5-mile 
radius, and only traps that contained mosquitoes are shown; empty traps are not displayed.
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